Redeye is raising its near-term earnings forecasts on the back of strong Q2 numbers.
Beyond Frames has unveiled that one of their ongoing projects is based on the multi-billion dollar I...
Redeye provides a brief comment on Modelon’s announcement of a two-year contract worth USD0.
Capitalising on the wave of infrastructure and defence investments 58% adj.
Redeye leaves a comment following Cinclus’ announcement of linaprazan glurate having received market...
On December 4th ODI Pharma provided an update regarding Poland’s expanding medical cannabis market.
Svag försäljning – återhämtning i sikte Nettoomsättningen minskade med 15,2 procent och kom in lägre...
MoveByBike Europe AB (”MoveByBike” eller ”Bolaget”) är ett hållbart logistikföretag som erbjuder hål...
Redeye provides a comment on Nanologica following the announcement of another order (marking the fou...
Redeye comments on the news that Egetis has decided to explore RTH-beta as the next indiction for ti...
Redeye is encouraged by the significant margin improvement achieved in the second quarter.
Redeye sees a Q2 report in line with our sales expectations but a bit heavier on the cost side.
Redeye leaves a comment following the promising recent interim data from Faron’s BEXMAB study and in...
BeammWave announced a joint pre-study with Alpha Networks, a fixed wireless access (FWA) challenger,...
Minor estimate revisions Subscription business performed well.
Contemplates issuance of SEK 250m bond (500m framework) Refinance of the SEK 250m bond issued in Q4'...
Sales of SEK 49m -38% q-o-q, EBIT back to negative at SEK -8m We lower FY'24/25e-FY'26/27e sales by ...
AcuCort har publicerat bolagets delårsrapport för det tredje kvartalet 2024 och annonserat en företr...
Ytterst positivt studieresultat Efter kvartalets slut meddelade bolaget att fas 1b-studien med STA36...
STENOCARE announced on December 2nd that the company’s premium product, the Astrum oil, has been app...